Core Viewpoint - During the "14th Five-Year Plan" period, China's medical insurance system has made significant progress in addressing urgent issues faced by the public, enhancing accessibility and affordability of medical services and medications [1][17]. Group 1: Medical Insurance Achievements - The implementation of centralized bulk purchasing and dynamic adjustments to the medical insurance drug list has enabled patients to access affordable medications and new treatments [1][5]. - The number of people benefiting from cross-provincial direct settlement of medical expenses has surged from 5.37 million in 2020 to 238 million in 2024, marking a 44-fold increase [13]. - The total expenditure of the medical insurance fund reached 12.13 trillion yuan during the "14th Five-Year Plan," with an average annual growth rate of 9.1% [15]. Group 2: Impact on Patients - The introduction of centralized procurement for high-value medical consumables, such as cochlear implants, has significantly reduced costs, with prices dropping from over 200,000 yuan to around 50,000 yuan [3][5]. - Innovative drugs, such as the newly approved treatment for rare lung cancer, have been included in the medical insurance directory, reducing patient costs from full out-of-pocket expenses to minimal payments after insurance coverage [9][11]. - The medical insurance coverage has expanded to include outpatient treatments for chronic diseases, providing greater financial relief for patients [11][13]. Group 3: Future Directions - The 11th batch of centralized procurement is underway, focusing on optimizing measures to ensure quality and affordability while promoting fair competition among pharmaceutical companies [7][9]. - The continuous improvement of the medical insurance system aims to enhance the accessibility and quality of healthcare services, ultimately contributing to the development of a healthier society [17].

Core Viewpoint - The National Healthcare Security Administration (NHSA) has introduced measures to support the high-quality development of innovative drugs, focusing on enhancing research support, facilitating access to insurance, and encouraging clinical application [1][2]. Summary by Relevant Sections Support for Innovative Drug Development - The NHSA has outlined 16 measures across five key areas to bolster innovative drug development, including support for research, inclusion in insurance directories, and enhancing payment capabilities [1][2]. - Approximately 80% of innovative drugs can be included in the insurance payment scope within two years of market launch [2]. Dynamic Adjustment Mechanism - A dynamic adjustment mechanism for the insurance directory has been established, reducing the adjustment cycle from a maximum of 8 years to 1 year, allowing for a more responsive inclusion of new drugs [2]. - The proportion of new drugs approved within five years that are included in the insurance directory has increased from 32% in 2019 to an expected 98% in 2024 [2]. Negotiation and Renewal Rules - The NHSA has improved negotiation and renewal rules for innovative drugs, focusing on patient clinical benefits to determine pricing [3]. - The number of first-class innovative drugs approved has significantly increased, with 48 new approvals expected in 2024, marking a fivefold increase since 2018 [3]. Encouragement of True Innovation - The measures emphasize the importance of supporting genuine and differentiated innovation in the pharmaceutical industry, addressing challenges such as homogenization and unclear clinical value [4][5]. - Since 2018, 149 innovative drugs have been included in the insurance directory, with total fund expenditures reaching 4.1 trillion yuan, driving significant sales growth [4]. Global Market Development - The NHSA aims to facilitate the global market expansion of innovative drugs, with over 90 overseas licensing transactions completed by Chinese pharmaceutical companies in 2024, totaling over $50 billion [7]. - The measures include building platforms for overseas market access and encouraging commercial health insurance to invest in innovative drugs [7][8]. Clinical Application and Usage - The NHSA encourages timely access to innovative drugs in designated medical institutions and supports the establishment of green channels for procurement [9]. - Measures have been introduced to enhance the capacity of medical institutions to use innovative drugs effectively, including optimizing payment standards and supporting special case applications [10].